Results 101 to 110 of about 125,515 (216)

Plasma Exosome Metabolomics Reveal Stage‐Specific Alterations in Elderly Women With Premetabolic and Metabolic Syndrome

Chronic Diseases and Translational Medicine, EarlyView.
Shared differential metabolites identified across the three sample groups. (A) Venn diagram of differential metabolites between the two comparison groups; Based on the detected levels of these overlapping differential metabolites, (B) d‐Arabitol, (C) Triclosan, (D) Iloprost, (E) Tetracosanoic acid, and (F) Omeprazole sulfone. Box plots were constructed
Mengtao Qian, Dan Nie, Qianyi Gao, Xingbo Mo, Huan Zhang   +4 more
wiley   +1 more source

Resistant hypertension, hyperaldosteronism, and the emerging understanding of hypercortisolism. [PDF]

Curr Opin Cardiol
Einhorn D, Mende C, Auchus RJ.
europepmc   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Prevalence of Obstructive Sleep Apnea Syndrome in Patients with Resistant Hypertension. [PDF]

J Clin Med
Ozyurt S, Taştan M, Gumus A, Beyazal Polat H, Ozcelik N.   +4 more
europepmc   +1 more source

Effect of Late Second to Early Third Trimester of Pregnancy on the Activity of Renal Organic Anion Transporters (OAT1 and OAT3): A Biomarker Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnant individuals take drugs throughout pregnancy and many of these drugs (e.g., antivirals, antibiotics) are eliminated by renal organic anion transporters (OAT) 1 and OAT3. In vivo studies with OAT1/3 substrate drugs suggest that pregnancy increases renal OAT1/3 activities by 1.5‐ to 1.8‐fold.
Aarzoo Thakur, Jashvant D. Unadkat, Emily E. Fay, Nina Isoherranen, Mary F. Hebert   +4 more
wiley   +1 more source

Current Management of Resistant Hypertension in Patients with Intracerebral Hemorrhage. [PDF]

Int J Mol Sci
Nguyen M, Oh S, King M, Yu W, Ramadan AR.   +4 more
europepmc   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

Distal radial artery access for renal denervation in resistant hypertension: a case report. [PDF]

Eur Heart J Case Rep
Zhao Y, Du Y, Tang Y, Yu M, Gao L.
europepmc   +1 more source

Role of selenium in the pathophysiology of cardiorenal anaemia syndrome

ESC Heart Failure, Volume 12, Issue 2, Page 770-780, April 2025.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple bidirectional mechanisms, and anaemia is one of the critical factors that are associated with the progression of the two disorders [referred to as cardiorenal anaemia syndrome (CRAS)].
Shigeyuki Arai, Minoru Yasukawa, Shigeru Shibata   +2 more
wiley   +1 more source

The Role of β-Blockers in the Evolving Treatment Landscape of Resistant Hypertension. [PDF]

Drugs
Masi S, Pathak A, Bruno RM, Brouwers S, Narkiewicz K, Taddei S, Tsioufis K, Kreutz R.   +7 more
europepmc   +1 more source